PT Kalbe Farma Tbk
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biop… Read more
PT Kalbe Farma Tbk (PTKFF) - Net Assets
Latest net assets as of September 2025: $24.67 Trillion USD
Based on the latest financial reports, PT Kalbe Farma Tbk (PTKFF) has net assets worth $24.67 Trillion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.95 Trillion) and total liabilities ($5.27 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $24.67 Trillion |
| % of Total Assets | 82.39% |
| Annual Growth Rate | 12.09% |
| 5-Year Change | 34.55% |
| 10-Year Change | 124.81% |
| Growth Volatility | 5.16 |
PT Kalbe Farma Tbk - Net Assets Trend (2005–2024)
This chart illustrates how PT Kalbe Farma Tbk's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PT Kalbe Farma Tbk (2005–2024)
The table below shows the annual net assets of PT Kalbe Farma Tbk from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $24.59 Trillion | +6.36% |
| 2023-12-31 | $23.12 Trillion | +4.63% |
| 2022-12-31 | $22.10 Trillion | +3.91% |
| 2021-12-31 | $21.27 Trillion | +16.36% |
| 2020-12-31 | $18.28 Trillion | +9.40% |
| 2019-12-31 | $16.71 Trillion | +9.23% |
| 2018-12-31 | $15.29 Trillion | +10.08% |
| 2017-12-31 | $13.89 Trillion | +11.47% |
| 2016-12-31 | $12.46 Trillion | +13.95% |
| 2015-12-31 | $10.94 Trillion | +11.42% |
| 2014-12-31 | $9.82 Trillion | +15.50% |
| 2013-12-31 | $8.50 Trillion | +15.31% |
| 2012-12-31 | $7.37 Trillion | +13.13% |
| 2011-12-31 | $6.52 Trillion | +12.89% |
| 2010-12-31 | $5.77 Trillion | +20.48% |
| 2009-12-31 | $4.79 Trillion | +10.27% |
| 2008-12-31 | $4.34 Trillion | +8.16% |
| 2007-12-31 | $4.02 Trillion | +13.34% |
| 2006-12-31 | $3.54 Trillion | +26.06% |
| 2005-12-31 | $2.81 Trillion | -- |
Equity Component Analysis
This analysis shows how different components contribute to PT Kalbe Farma Tbk's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1160.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $22.94 Trillion | 100.67% |
| Common Stock | $468.75 Billion | 2.06% |
| Total Equity | $22.79 Trillion | 100.00% |
PT Kalbe Farma Tbk Competitors by Market Cap
The table below lists competitors of PT Kalbe Farma Tbk ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shandong Weigao Group Medical Polymer Company Limited
F:UK2
|
$1.36 Billion |
|
Peker Gayrimenkul Yatirim Ortakligi AS
IS:PEKGY
|
$1.36 Billion |
|
Fujian Funeng Co Ltd
SHG:600483
|
$1.36 Billion |
|
Sally Beauty Holdings Inc
NYSE:SBH
|
$1.36 Billion |
|
Killam Apartment Real Estate Investment Trust
TO:KMP-UN
|
$1.36 Billion |
|
Progyny Inc
NASDAQ:PGNY
|
$1.36 Billion |
|
Zeon Corporation
PINK:ZEOOY
|
$1.36 Billion |
|
Technogym SpA
LSE:0RG1
|
$1.36 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PT Kalbe Farma Tbk's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 21,418,856,503,057 to 22,788,879,435,000, a change of 1,370,022,931,943 (6.4%).
- Net income of 3,240,636,626,000 contributed positively to equity growth.
- Dividend payments of 1,433,930,309,000 reduced retained earnings.
- Share repurchases of 460,484,944,000 reduced equity.
- New share issuances of 3,088,500,000 increased equity.
- Other comprehensive income decreased equity by 825,444,612,956.
- Other factors increased equity by 846,157,671,899.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $3.24 Trillion | +14.22% |
| Dividends Paid | $1.43 Trillion | -6.29% |
| Share Repurchases | $460.48 Billion | -2.02% |
| Share Issuances | $3.09 Billion | +0.01% |
| Other Comprehensive Income | $-825.44 Billion | -3.62% |
| Other Changes | $846.16 Billion | +3.71% |
| Total Change | $- | 6.40% |
Book Value vs Market Value Analysis
This analysis compares PT Kalbe Farma Tbk's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $45.95 | $0.08 | x |
| 2006-12-31 | $58.98 | $0.08 | x |
| 2007-12-31 | $67.13 | $0.08 | x |
| 2008-12-31 | $74.27 | $0.08 | x |
| 2009-12-31 | $90.01 | $0.08 | x |
| 2010-12-31 | $114.65 | $0.08 | x |
| 2011-12-31 | $132.58 | $0.08 | x |
| 2012-12-31 | $150.49 | $0.08 | x |
| 2013-12-31 | $172.98 | $0.08 | x |
| 2014-12-31 | $200.15 | $0.08 | x |
| 2015-12-31 | $223.26 | $0.08 | x |
| 2016-12-31 | $254.06 | $0.08 | x |
| 2017-12-31 | $283.32 | $0.08 | x |
| 2018-12-31 | $311.97 | $0.08 | x |
| 2019-12-31 | $339.05 | $0.08 | x |
| 2020-12-31 | $371.33 | $0.08 | x |
| 2021-12-31 | $417.71 | $0.08 | x |
| 2022-12-31 | $438.24 | $0.08 | x |
| 2023-12-31 | $463.05 | $0.08 | x |
| 2024-12-31 | $493.81 | $0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PT Kalbe Farma Tbk utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.22%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.93%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 1.29x
- Recent ROE (14.22%) is below the historical average (20.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 30.22% | 12.01% | 1.27x | 1.99x | $471.71 Billion |
| 2006 | 25.52% | 12.59% | 1.31x | 1.54x | $464.88 Billion |
| 2007 | 23.96% | 11.59% | 1.36x | 1.52x | $472.96 Billion |
| 2008 | 22.79% | 10.48% | 1.38x | 1.57x | $463.26 Billion |
| 2009 | 24.35% | 11.55% | 1.40x | 1.50x | $618.62 Billion |
| 2010 | 25.01% | 13.14% | 1.45x | 1.31x | $806.42 Billion |
| 2011 | 24.51% | 13.96% | 1.32x | 1.33x | $901.48 Billion |
| 2012 | 24.58% | 12.72% | 1.45x | 1.34x | $1.03 Trillion |
| 2013 | 23.67% | 12.00% | 1.41x | 1.40x | $1.11 Trillion |
| 2014 | 22.01% | 11.89% | 1.40x | 1.32x | $1.13 Trillion |
| 2015 | 19.15% | 11.20% | 1.31x | 1.31x | $957.72 Billion |
| 2016 | 19.31% | 11.87% | 1.27x | 1.28x | $1.11 Trillion |
| 2017 | 18.10% | 11.91% | 1.21x | 1.25x | $1.08 Trillion |
| 2018 | 16.80% | 11.66% | 1.16x | 1.24x | $994.78 Billion |
| 2019 | 15.77% | 11.08% | 1.12x | 1.28x | $917.45 Billion |
| 2020 | 15.70% | 11.83% | 1.02x | 1.30x | $992.71 Billion |
| 2021 | 16.26% | 12.12% | 1.02x | 1.31x | $1.23 Trillion |
| 2022 | 16.59% | 11.69% | 1.06x | 1.34x | $1.34 Trillion |
| 2023 | 12.92% | 9.09% | 1.13x | 1.26x | $624.86 Billion |
| 2024 | 14.22% | 9.93% | 1.11x | 1.29x | $961.75 Billion |
Industry Comparison
This section compares PT Kalbe Farma Tbk's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $355,057,678,100
- Average return on equity (ROE) among peers: -0.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PT Kalbe Farma Tbk (PTKFF) | $24.67 Trillion | 30.22% | 0.21x | $1.36 Billion |
| AbbVie Inc (ABBV) | $15.70 Billion | 26.61% | 0.35x | $387.90 Billion |
| Astellas Pharma Inc (ALPMF) | $1.46 Trillion | 8.50% | 0.60x | $16.93 Billion |
| Amgen Inc (AMGN) | $80.60 Million | 0.62% | 0.16x | $194.15 Billion |
| Amarin Corporation PLC (AMRN) | $24.15 Million | -158.05% | 0.75x | $303.32 Million |
| AstraZeneca PLC (AZN) | $14.91 Billion | 37.51% | 2.22x | $295.24 Billion |
| Bayer AG (BAYZF) | $20.80 Billion | 15.33% | 1.47x | $21.61 Billion |
| Biogen Inc (BIIB) | $6.43 Billion | 19.21% | 0.41x | $27.11 Billion |
| Bristol-Myers Squibb Company (BMY) | $4.75 Billion | 22.46% | 0.58x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $2.03 Trillion | 21.42% | 0.22x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $58.37 Million | 6.18% | 0.57x | $529.97 Million |